Evidence map›Paper›PMID 32848428›Full record

ReviewInfection and drug resistance2020

Advantages and Challenges of Tailored Regimens for Drug-Resistant Tuberculosis: A StopTB Italia Look into the Future.

Niccolò Riccardi, Simone Villa, Riccardo Alagna, Andrea Giacomelli, Laura Saderi, Daniela Maria Cirillo, Giorgio Besozzi, Giovanni Sotgiu, Luigi Codecasa

Open access · goldAbstract readReview
In one paragraph

Review in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Journal of preventive medicine and hygiene · 2021
    Article
  7. Tuberculosis and pharmacological interactions: A narrative review.Current research in pharmacology and drug discovery · 2021
    Review
  8. Drug Resistance Pattern ofInfection and drug resistance · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Niccolò Riccardi *StopTB Italia Onlus, Milan 20159, Italy.ORCID 0000-0002-2947-4707
Simone Villa *StopTB Italia Onlus, Milan 20159, Italy.ORCID 0000-0002-0753-8853
Riccardo AlagnaStopTB Italia Onlus, Milan 20159, Italy.
Andrea GiacomelliStopTB Italia Onlus, Milan 20159, Italy.ORCID 0000-0003-3685-4289
Laura SaderiStopTB Italia Onlus, Milan 20159, Italy.ORCID 0000-0002-5131-9367
Daniela Maria CirilloStopTB Italia Onlus, Milan 20159, Italy.
Giorgio BesozziStopTB Italia Onlus, Milan 20159, Italy.ORCID 0000-0002-2041-8493
Giovanni SotgiuStopTB Italia Onlus, Milan 20159, Italy.ORCID 0000-0002-1600-4474
Luigi CodecasaStopTB Italia Onlus, Milan 20159, Italy.
Associazione Italiana Vulvodinia Onlus · ITUniversity of Sassari · ITVita-Salute San Raffaele University · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITOspedale Sacro Cuore Don Calabria · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emerge of drug-resistant tuberculosis (TB) strain in recent decades is hampering the efforts of the international community to eliminate the disease worldwide. The World Health Organization (WHO) has drafted many strategies to achieve this ambitious goal. In the very beginning, the aim was to standardize inadequate regimens used in many countries and, thereafter, evolved to tackle the social determinants which hinder TB elimination. However, following the path of narrowing the clinical vision to deal with TB, there is an increased need to personalize the treatment considering both patients and pathogen unique characteristics. In our narrative review, we report the advantages and the backwards in developing a method to implement the concept of precision medicine to the treatment of TB. In this dissertation, we highlight the importance to address different aspects of the diseases encompassing the host and pathogen features, as well as the needs to further implement an adequate follow-up based on the available resources. Nevertheless, many things may hamper the vision of precision medicine in TB, such as the complexity and the costs to develop novel compounds and the costs related to global-scale implementation of patient-centered follow-up. To achieve the ambitious goal of TB elimination, a radical change in TB treatment is needed in order to give a more comprehensive approach based both on patients' peculiarities and driven by drug susceptibility tests and whole-genome sequencing.

Indexed as

drug-resistanceStopTBtailoredtreatmenttuberculosis

Identifiers

PMID32848428
PMCPMC7429110
OpenAlexW3048879937

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.